Investigating calcium signaling in heart disease
Official title: Crosstalk Ca2+ Signaling between Ryanodine Receptors Type 1 and 2 in the Pathogenesis of Cardiac Hypertrophy and Heart Failure
Funded at Thomas Jefferson University · NIH-11052467 · Data updated 2026-11-12
This study is looking at how certain signals in heart cells can affect heart health, especially in people with heart failure, by using mice to understand how these signals change when the heart is under stress, which could help find new treatments for heart problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $568,440 |
| NIH project number | 5R01HL164941-03 |
| Project ID | NIH-11052467 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with heart failure or those at risk of developing cardiac hypertrophy.
✕Less likely to help
Patients with non-cardiac related conditions or those without heart disease may not receive any benefit from this research.
What this research studies
This research explores how calcium signaling between specific receptors in heart cells contributes to heart failure and cardiac hypertrophy. By examining the role of ryanodine receptors in energy regulation within heart cells, the study aims to uncover the molecular mechanisms that lead to heart dysfunction. The approach involves using mouse models to analyze changes in calcium levels and energy production in heart cells under stress conditions. Patients may benefit from insights gained that could lead to new treatments for heart conditions.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating heart failure and improving heart function.
How similar studies have gone: Previous research has shown promising results in understanding calcium signaling in heart disease, indicating that this approach has potential for success.
Where this research is happening
-
Thomas Jefferson University
Philadelphia, United States Active
Researchers
- Principal investigator: Sheu, Shey-Shing — Thomas Jefferson University
- Study coordinator: Sheu, Shey-Shing
Related research
Other NIH-funded projects on the same topics.
-
AI-supported heart failure diagnosis and management in Rwanda
Aiming to help people with suspected heart failure in Rwanda get faster, more accurate diagnoses and better care using AI-guided ultrasound and care protocols.
-
AI-assisted heart failure diagnosis in Rwanda using focused ultrasound
An NIH-funded project will test whether AI-enhanced, easy-to-use heart ultrasound can help non-experts diagnose and manage heart failure in Rwanda.
-
HF endotypes in heart failure using ethical multi-modal AI and molecular data
A patient-friendly project that uses advanced AI and multiple kinds of health data to identify distinct heart failure subtypes that could guide personalized care.
-
Triple gene therapy approach to heal the heart after a heart attack
A new therapy combines three genetic approaches delivered by a virus to help the heart heal after a heart attack.
-
Digital-first heart failure care delivery in Uganda
A targeted program in Uganda tests a digital care plan to help people with heart failure manage their symptoms at home.
-
Digital-first heart failure care delivery in Uganda
A study to test digital self-care tools to help people with heart failure in Uganda manage symptoms and stay healthier.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.